DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
Oppenheimer - 4 Jay Olson - 3 Goldman Sachs - 2 Eli Lilly's Zepbound - 2 Jed Kelly - 1 DKNG - 1 NASH - 1 Timothy Horan - 1
Top related locs:
Zeta Novo New York City Branchburg , New Jersey
Top related orgs:
Viking Therapeutics - 3 Nasdaq - 1 Dow Jones - 1 Biotechnology - 1 Telecommunications - 1 AT - 1 JPMorgan - 1 Broadcom - 1

Search resuls for: "Jay Olson"


5 mentions found


☆ Oppenheimer's top stock ideas heading into October
  + stars: | 2024-09-26 | by ( Sean Conlon | ) www.cnbc.com   time to read: +4 min
This comes after all three major averages recovered from the Aug. 5 global sell-off to close out last month higher. DKNG YTD mountain DKNG, year-to-date Biotechnology stock Viking Therapeutics also made the list. The stock has already surged more than 239% this year as its experimental obesity treatment advances through clinical trials. Telecommunications stock AT & T was another best idea, with its target of $23 implying more than 6% upside. Other names that made the list include Cigna , whose target implies more than 14% upside, and chip giant Broadcom .
Persons: Oppenheimer, Goldman Sachs, Jed Kelly, DKNG, Jay Olson, NASH, Timothy Horan, Horan isn't Organizations: Nasdaq, Dow Jones, Biotechnology, Viking Therapeutics, Telecommunications, AT, JPMorgan, Broadcom
☆ The best small- and midcap stocks to buy this summer, according to Oppenheimer
  + stars: | 2024-07-10 | by ( Sean Conlon | ) www.cnbc.com   time to read: +3 min
With the second half of the year underway, Oppenheimer is highlighting what it calls its top small- and midcap seasonal standout investment ideas. On the basis of price charts alone, Oppenheimer tapped midcap growth stocks as its top rotation idea from a technical perspective. Oppenheimer has a $20 price target on Zeta, implying 18% upside from Tuesday's close. In a note last month, RBC Capital Markets also rated Zeta outperform with a price target of $20. In this area, Oppenheimer likes Viking Therapeutics , reiterating the stock as one of its best ideas.
Persons: Oppenheimer, Russell, Brian Schwartz, Zeta, Novo Nordisk's Wegovy, Eli Lilly's Zepbound, Jay Olson, Freshpet Organizations: Oppenheimer, Zeta Global Holdings, Zeta, RBC Capital Markets, Novo Nordisk's, Viking Therapeutics, Therapeutics Locations: Zeta, Novo
☆ Viking Therapeutics emerges as a strong weight loss drug player — or takeover target
  + stars: | 2024-03-03 | by ( Annika Kim Constantino | ) www.cnbc.com   time to read: +8 min
In this article VKTX Follow your favorite stocks CREATE FREE ACCOUNTCr | Istock | Getty ImagesBiotech company Viking Therapeutics has emerged as a strong potential entrant — or takeover target — in the budding weight loss drug market. Their treatments sparked the weight loss drug industry gold rush over the past year despite their hefty price tags and barriers to insurance coverage. It's too early to say whether Viking's drug could have an edge over existing or developing weight loss treatments. The pharmaceutical giant could also launch a slate of other weight loss treatments over the next few years that may have advantages over Zepbound, whether they offer more weight loss or convenience. That could give Viking the commercial and manufacturing capabilities needed to compete in the weight loss drug market.
Persons: Eli Lilly, Eli Lilly's Zepbound, Viking, Goldman Sachs, Eli Lilly’s, Brendan Mcdermid, GLP, Brian Lian, William Blair, Andy Hsieh, Hsieh, Eli Lilly's, Jefferies, Akash Tewari, doesn't, Mike Segar, Lian, William Blair's Hsieh, Oppenheimer, Jay Olson Organizations: Getty Images Biotech, Viking Therapeutics, Novo Nordisk, Reuters, Viking, Novo, U.S . Food, Drug Administration, Company, Deutsche Bank, CNBC Locations: New York City, Branchburg , New Jersey
☆ Viking's obesity drug study results are 'almost flawless', says Oppenheimer's Jay Olson
  + stars: | 2024-02-27 | by ( ) www.cnbc.com   time to read: 1 min
In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailViking's obesity drug study results are 'almost flawless', says Oppenheimer's Jay OlsonJay Olson, Oppenheimer biotech analyst, joins 'Fast Money' to talk Viking's best trading day ever and the results of its obesity drug study.
Persons: Oppenheimer's Jay Olson Jay Olson, Oppenheimer
☆ Oppenheimer says investors are missing opportunities in three biotech areas and the related stocks
  + stars: | 2023-05-16 | by ( Christina Cheddar Berk | ) www.cnbc.com   time to read: +4 min
As biopharma investors follow the latest buzz around advancements in clinical research, they may be under-appreciating opportunities in neurology, psychiatry and genetic medicine, according to a report from Oppenheimer. "Valuation multiples across disease areas show CNS [ or central nervous system] and Genetic Medicine at relative low points." In July, the Food and Drug Administration could grant full approval to Leqembi , its Alzheimer's Disease treatment. As a very new area of medicine, gene therapy has greatest potential to accelerate sales growth as treatments come to market. He described immunology multiples as "generally stable" and genetic medicine multiples as highly volatile.
0 next >>
Total: 5